Funding Opportunities

Winship researchers receive funding through a variety of awards and grants. View a selection of federal and private funding opportunities for which Winship researchers may be eligible to apply.

Society for Immunotherapy of Cancer Fellowships

The Society for Immunotherapy of Cancer (SITC) is offering three fellowship opportunities to support the development of the next generation of cancer immunotherapy experts.

1. SITC’s Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Award

  • One year, $100,000 award to support the research of a young investigator in the translational cancer immunotherapy space.

    Eligibility
  • Hold an MD, PhD or combined MD/PhD degree
  • Currently hold a position at a leading academic cancer center as a postdoctoral fellow, resident, research scientist or comparable position
  • Be within postdoctoral or postgraduate training, or no more than four years from completing such training
  • Commit 75% of workday to research supported by the fellowship
  • Be a current SITC member. (Not a member? Join today at sitcancer.org.)

Application Deadline: February 20, 2017
Apply Online: sitcancer.org/funding/fellowships/2017/kohrt-genentech
Contact: SITC Development at development@sitcancer.org or (414) 271-2456

2. SITC-Merck Immunotherapy in Lung Cancer Clinical Fellowship Award

  • One year, $100,000 fellowship award to support the development of the next generation of immunotherapy experts who have a vested interest in furthering the clinical research and translation of cancer immunotherapy in lung cancer.

    Eligibility
  • Hold an MD or combined MD/PhD degree
  • Currently hold a position at a leading academic cancer center as a postdoctoral fellow, resident, research scientist or comparable position
  • Be within postdoctoral or postgraduate training, or no more than four years from completing such training
  • Commit 75% of workday to research supported by the fellowship
  • Be a current SITC member. (Not a member? Join today at sitcancer.org.)

Application Deadline: February 20, 2017
Apply Online: sitcancer.org/funding/fellowships/2017/merck
Contact: SITC Development at development@sitcancer.org or (414) 271-2456

3. NCI Immunotherapy Fellowship

  • One-year program co-sponsored by the National Cancer Institute of the National Institutes of Health and SITC and made possible in part by an educational grant from EMD Serono
  • Conducted at the Center for Cancer Research (CCR) in Bethesda, MD, fellows are exposed to multiple clinical immunotherapeutic approaches, and also to key opinion leaders in the field of clinical immunotherapy.

    Eligibility
  • Able to relocate to Bethesda, MD for the duration of the fellowship
  • Trained in Medical Oncology, Hematology, Pediatric Oncology, Radiation Oncology, or Surgical Oncology
  • Interest in learning about immunotherapy
  • Preference is given to those with an academic interest
  • Open to US and Non-US trained physicians

Application Deadline: February 20, 2017
Apply Online: sitcancer.org/funding/fellowships/2017/nci

V Foundation Translational Research Grant

The V Foundation seeks to support translational research projects within the scope of all types of cancers. The Translational Research Award is a $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted. 

V Foundation definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

V Foundation Special Focus area: As in previous years, any area of cancer research is permitted. However, research on cancers that are more prevalent or aggressive in specific ethnic populations is encouraged, but not required. Cancers in which ethnic and racial disparities have previously been shown include: lung and bronchus, colon and rectum, breast, prostate, uterine, cervix, stomach and liver. As in 2016, among V Foundation’s highly ranked finalists for the 2017 Translational Award program, they will designate at least one of the highest ranked applications as the recipient of their Stuart Scott Memorial Fund Translational Research Award. While not required, V Foundation has a special interest in supporting immune oncology and immunotherapy research, when applicable.

Eligibility

  • Scientists who hold a tenure-track faculty position at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team.
  • Applicants must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).

Letters of Intent
Letters of Intent (not to exceed 2 pages) are due February 24, 2017 via email to winshipgrants@emory.edu. Letters of Intent should also include the PI’s NIH Biosketch, a proposed title for the research project, and a brief 1-2 page abstract of the proposed research project. The selected investigators will be notified and invited to submit a full application by Winship.

Letter of Intent Deadline: 5:00 PM EST on Friday, February 24, 2017

Announcement of Nominee Selection: Friday, March 10, 2017

Translational Application Due Date: 5:00 PM EST on Tuesday, May 2, 2017

Pancreatic Cancer Research Grants

The Pancreatic Cancer Action Network is now accepting applications for its 2017 funding opportunities.

Precision Medicine Targeted Grant
Amount: Up to $1,000,000
Duration: Up to two years
Funding available for projects that can be incorporated directly into the Pancreatic Cancer Action Network’s Precision Promise initiative at the end of the funding period.
Application Deadline: Noon EST, February 15, 2017
 
Early Detection Targeted Grant
Amount: Up to $1,000,000 in milestone-driven units of $250,000
Duration: Up to four years
Supports studies to utilize a cohort of new onset diabetics with high risk of sporadic pancreatic cancer; projects 
Application Deadline: Noon EST, February 22, 2017
 
KRAS Travel Scholarship
(in partnership with the NCI Frederick National Laboratory for Cancer Research)
Provides travel support to a researcher at any career stage, during or after the postdoctoral level, to visit FNLCR to pursue KRAS research that is directly relevant to pancreatic cancer with aims aligned with the RAS Initiative
Amount: Depending on need
Application Deadline: Rolling

Aplastic Anemia and MDS International Foundation Grants

For more than 20 years, the Aplastic Anemia and MDS International Foundation (AAMDISF) has provided investigators with financial support for research that leads to new insights into the causes of bone marrow failure and the development of new therapeutic approaches. Successful grant applicants can be funded up to $60,000 for two years ($30,000 each year, with second-year funding pending approved progress in the first year). Detailed criteria and applications instructions are available at https://proposalcentral.altum.com.

Eligibility

To be eligible to apply for a research grant, an applicant must hold a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Science, or other doctoral level degree (e.g., PharmD). There are no nationality restrictions. The project must represent independent research conducted by the applicant.

Grants can be awarded to new investigators and established Investigators.  New investigators are post-doctoral fellows, instructors and those who have been assistant professors for fewer than five (5) years.  Established Investigators have been assistant professors for five (5) years or more or are associate or full professors. Preference will be given to applications submitted by new investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research.

Topic areas considered for funding include:

  • Promoting understanding of the etiology and pathogenesis of aplastic anemia, MDS or PNH;
  • Improving symptom management and the quality of life for aplastic anemia, MDS or PNH patients;
  • Discovering new treatments for aplastic anemia, MDS or PNH;
  • Understanding and preventing complications of bone marrow failure conditions (e.g., blood clotting/thrombosis in PNH, iron overload in MDS, etc.); and,
  • Research regarding inherited bone marrow failure disorders, provided a strong case is also made for pertinence of the research to acquired disorders.

In addition, the following criteria will be considered by reviewers:

  • The likelihood that the goals of the proposal are attainable with the funding from AAMDSIF;
  • The project is independent research and not part of a large, multi-funded study;
  • The translational nature of the research and whether the findings can be rapidly applied to benefit patients; and,
  • For new investigators, the likelihood that the project will contribute toward the professional development of the researcher.
  • Applications that do not fall within the selection criteria, or that address a disease outside of our scope (e.g., acute leukemia), will be disqualified.  
Application Deadline: February 28, 2017

HERCULES-Winship Partnership: Cancer and the Environment

The HERCULES Exposome Research Center announces its 2017 Pilot Project Program in Environmental Health Sciences, which includes a jointly supported pilot with Winship Cancer Institute. Applications for the HERCULES-Winship award will focus on the role of the environment in cancer biology and cancer prevention, and include at least one investigator who is a member of Winship. All applications must focus on the role of the environment in human disease. Projects can include basic, biomedical, translational, clinical, epidemiological, behavioral or community-based participatory research (CBPR) approaches.  

Eligibility

Awards are open to investigators at Emory and Georgia Tech who are eligible to serve as Principal Investigators on NIH grant applications (instructor and above, tenure-, research- or clinical-track). All applicants interested in funding from the HERCULES-Winship partnership should include at least one investigator who is a member of Winship. Projects with translational relevance (clinical or population-based), applications from early-career investigators, and collaborative and interdisciplinary projects are particularly encouraged.

Application Deadline: Monday, March 20, 2017 at 5:00 PM

Funding Cycle: May 1, 2017 to March 31, 2018

Contact: Kate Hodgins, katehodgins@emory.edu

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents.  Specifically, this program announcement encourages research grant applications to:

  1. Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; 
  2. Identify structural, systemic, and psychosocial barriers to adherence; and 
  3. Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.   

PA-17-060 (R01)
PA-17-061 (R21)

Standard application due dates apply.

Cascade Link  TOP